Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
09/2005
09/22/2005WO2005087727A1 Novel alkyl-containing 5-acylindolinones, their preparation and their use as pharmaceutical products
09/22/2005WO2005087713A1 Amide compound, pharmaceutical composition and rxr function control agent
09/22/2005WO2005087710A1 Aminophenylpropanoic acid derivative
09/22/2005WO2005087247A1 Blood cholesterol level-lowering agent
09/22/2005WO2005087182A1 Functional powders
09/22/2005WO2005087025A1 Composition; use of a composition and a method for treating obesity
09/22/2005WO2005087023A1 The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and metabolic syndrome
09/22/2005WO2005063232A8 Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
09/22/2005WO2000075279A3 Nucleotide sequences for gene regulation and methods of use thereof
09/22/2005US20050209341 R-(-)-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane or its hydrochloride salt; inhibiting the uptake of norepinephrine and serotonin; antidepressants, analgesics; treating sleep disorders, autism, psychological disorders, eating disorders
09/22/2005US20050209329 Potentiation of therapeutic effects of fatty acids
09/22/2005US20050209325 Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators
09/22/2005US20050209309 Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same
09/22/2005US20050209306 Crystalline [R-(R*,R*)]-2-(4-fluorophenyI)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl- 4-[(phenylamino)carbonyl]-1H-pyrrole-heptanoic acid calcium salt (2:1)
09/22/2005US20050209302 Glycogen synthase kinase (GSK-3) inhibitors; diabetes, neurodegenerative diseases, stroke, neurotraumatic injuries and bipolar disorders; 5-acetyl-3-[3-(methoxycarbonylpropylamino)-(benzo-[1.3]dioxyo-5-yl)-methylidene]-2-indolinone for example
09/22/2005US20050209286 RXR activating molecules
09/22/2005US20050209273 Neuroprotectants, analgesics or anticonvulsants
09/22/2005US20050209252 Using an indazole compound
09/22/2005US20050209244 N{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
09/22/2005US20050209240 such as 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}oxime; phosphodiesterase IV inhibitors
09/22/2005US20050209233 Neuropeptide Y5 (NPY-5) receptor antagonists or agonists; eating disorders, diabetes dyslipidemia, hypertension, and sleep disorders; pyridazin-3-ylamino-substituted dibenzothiophenes and S-oxides thereof
09/22/2005US20050209225 Substituted indoles and their use as integrin antagonists
09/22/2005US20050209213 Quinoline compound
09/22/2005US20050209192 Autoimmune disorders; modulating protein kinase C activity
09/22/2005US20050209166 Metabolic disorders like diabetes; inhibits sodium-dependent glucose cotransporter; 1-chloro-2-(4-cyclopentyloxybenzyl)-4-( beta -D-glucopyranos-1-yl)-benzene
09/22/2005US20050209159 Effectors of dipeptidyl peptidase IV for topical use
09/22/2005US20050209151 Administering a ligand peptide for a G protein-coupled receptor protein for regulating the secretion of corticotropin-releasing hormones; hypoaldosteronism, hypocortisolemia, secondary or chronic hypoadrenocorticism, Addison's disease, adrenal dysfunction, or obesity
09/22/2005US20050209128 Statins, especially (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, as nerve conduction velocity or nerve blood flow enhancers in combination with an aldose reductase inhibitor, an ACE inhibitor or an Angiotensin II antagonist
09/22/2005US20050208580 Novel protein and method for producing the protein
09/22/2005US20050208552 Corpuscles of Stannius protein, stanniocalcin
09/22/2005US20050208525 Nucleotide sequences coding preferential polypeptide for use in the treatment defects in immune and inflammatory response
09/22/2005US20050208198 Ultrafiltration/microfiltration to separate fibers from starch residues; electrodialysis
09/22/2005US20050208163 anticholesterol agents contains Persea americana var. drymifolia leaf plant extract; nutraceuticals
09/22/2005US20050208161 touchi plant extract and phaseolamin mixture for limiting the absorption of carbohydrates contained in a foodstuff, for promoting weight loss in an individual; nutraceuticals
09/22/2005US20050208135 Monocompartment osmotic controlled drug delivery system
09/22/2005US20050208061 Treatment of autoimmune diseases by oral administration of autoantigens
09/22/2005US20050208053 Administering very late antigen-4, antigen binding fragment thereof, soluble vascular cell adhesion molecule-1 polypeptide; chimera
09/22/2005US20050208042 Inducing lack of responsiveness to an antigen in an individual having a transplanted organ, tissue, cell; administering an effective amount of a humanized antibody; one antigen binding region of nonhuman origin and a portion of an immunoglobulin heavy chain of human origin
09/22/2005US20050208035 Nutritional composition for treating an immune condition
09/22/2005US20050208029 Method of forming pancreatic beta cells from mesenchymal cells
09/22/2005US20050208001 rosacea, intrinsic or chronological aging, pigmentation, seborrhoeic function, barrier function, epidermal lipid secretion, wound healing, atrophies, ulcers, immune system, cardiovascular system disorders; 6-(5,6,7,8-tetrahydro-5,5,8,8-tetra-methylnaphthalene-2-carbonyl)naphthalene-2-carboxylic acid
09/22/2005DE102004010254A1 New 4-heterocyclyl-1-acyl-piperidine derivatives, useful e.g. for treating headache, diabetes and cardiovascular disease, are antagonists of calcitonin-gene related peptide
09/22/2005DE10100772B4 Ether- und Amidverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Antidiabetika Ether and amide compounds, processes for their preparation and their use as antidiabetic agents
09/22/2005CA2581424A1 Methods for generating insulin-producing cells
09/22/2005CA2560111A1 Aminophenylpropanoic acid derivative
09/22/2005CA2560098A1 2-aminoquinazoline derivative
09/22/2005CA2559175A1 Composition; use of a composition and a method for treating obesity
09/22/2005CA2559139A1 Novel alkyl-containing 5-acylindolinones, their preparation and their use as pharmaceutical products
09/22/2005CA2559060A1 Phospholipases, nucleic acids encoding them and methods for making and using them
09/21/2005EP1577388A1 Adiponectin promoter and use thereof
09/21/2005EP1577323A1 Metastin derivative and use thereof
09/21/2005EP1577317A1 Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
09/21/2005EP1577299A1 Alkynyl-substituted azasugar derivative and drug containing the same as the active ingredient
09/21/2005EP1577288A1 Selective estrogen receptor modulators
09/21/2005EP1576964A1 Protease inhibitor
09/21/2005EP1576960A1 Composition containing green and yellow vegetables and light-colored vegetables
09/21/2005EP1576956A2 Chromium/biotin treatment of type II diabetes
09/21/2005EP1576370A2 Methods of diagnosing and treating diabetes and insulin resistance
09/21/2005EP1576168A2 Therapeutic polypeptides nucleic acids encoding same and methods of use
09/21/2005EP1576088A2 Dominant negative proteins and methods thereof
09/21/2005EP1576086A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
09/21/2005EP1575964A2 N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists
09/21/2005EP1575942A1 Novel compounds having selective inhibiting efect at gsk3
09/21/2005EP1575939A1 Novel compounds having selective inhibiting effect at gsk3
09/21/2005EP1575938A1 Novel compounds having selective inhibiting effect at gsk3
09/21/2005EP1575912A1 Variously substituted derivatives of guanidine, and their use as medicines with anti-diabetes and/or anti-obesity activity
09/21/2005EP1575671A1 Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone
09/21/2005EP1575593A2 Use of von tetrahydrobiopterine derivatives in the treatment and nutrition of patients with amino acid metabolic disorders
09/21/2005EP1575587A1 Iminosugar derivatives as glucosidase inhibitors
09/21/2005EP1575575A2 Safe chemical uncouplers for the treatment of obesity
09/21/2005EP1575528A2 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
09/21/2005EP1575524A2 Proliferated cell lines and uses thereof
09/21/2005EP1575499A2 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
09/21/2005EP1575480A2 Compositions and methods for the treatment of immune related diseases
09/21/2005EP1438038A4 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
09/21/2005EP1420790B1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
09/21/2005EP1303501B1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging
09/21/2005EP1299382B1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
09/21/2005EP1294877B1 Cgi-69 compositions and methods of use
09/21/2005EP1282602B1 Propanoic acid derivatives as integrin receptor antagonists
09/21/2005EP1189522B1 Use of nanoscale sterols and sterol esters
09/21/2005EP1163217B1 New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
09/21/2005EP0996459B1 Use of exendins and agonists thereof for the reduction of food intake
09/21/2005EP0712303B1 Skin patches comprising testosterone and optionally estrogen
09/21/2005CN1671856A Novel physiologically active substances
09/21/2005CN1671835A A method for the establishment of a pluripotent human blastocyst-derived stem cell line
09/21/2005CN1671744A Low molecular weight oversulfated polysaccharide
09/21/2005CN1671730A Oligonucleotide-containing pharmacological compositions and their use
09/21/2005CN1671723A Novel difluorinated gem compounds, preparation methods thereof and applications of same
09/21/2005CN1671715A Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors
09/21/2005CN1671714A Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
09/21/2005CN1671701A Novel aryllimidazole derivatives, preparation and therapeutic used thereof
09/21/2005CN1671696A 激酶抑制剂 Kinase inhibitors
09/21/2005CN1671694A Bisindolyl-maleimid derivatives as kinase inhibitors
09/21/2005CN1671682A Azulene derivatives and salts thereof
09/21/2005CN1671668A 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
09/21/2005CN1671666A Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines
09/21/2005CN1671662A Piperidine derivative, process for producing the same, and use
09/21/2005CN1671421A Inclusion complexes of rosiglitazone
09/21/2005CN1671407A Compositions and methods for treating diabetes
1 ... 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 ... 1298